LLY

1,032.58

-1.41%↓

JNJ

245.04

-0.69%↓

ABBV

227.5

-0.56%↓

NVS

167.75

+0.08%↑

MRK

122.62

-1.57%↓

LLY

1,032.58

-1.41%↓

JNJ

245.04

-0.69%↓

ABBV

227.5

-0.56%↓

NVS

167.75

+0.08%↑

MRK

122.62

-1.57%↓

LLY

1,032.58

-1.41%↓

JNJ

245.04

-0.69%↓

ABBV

227.5

-0.56%↓

NVS

167.75

+0.08%↑

MRK

122.62

-1.57%↓

LLY

1,032.58

-1.41%↓

JNJ

245.04

-0.69%↓

ABBV

227.5

-0.56%↓

NVS

167.75

+0.08%↑

MRK

122.62

-1.57%↓

LLY

1,032.58

-1.41%↓

JNJ

245.04

-0.69%↓

ABBV

227.5

-0.56%↓

NVS

167.75

+0.08%↑

MRK

122.62

-1.57%↓

Home・Список акций・Vivani Medical

Vivani Medical

Закрыт

1.26 0.8

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.21

Макс.

1.28

Ключевые показатели
By Trading Economics
Сотрудники	37

Дивиденды
By Dow Jones
Следующий отчет о доходах	30 мар. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-19M 86M
Предыдущая цена открытия	0.46
Предыдущая цена закрытия	1.26

Vivani Medical График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 февр. 2026 г., 23:07 UTC

Отчет

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 февр. 2026 г., 23:01 UTC

Отчет

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 февр. 2026 г., 22:59 UTC

Отчет

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 февр. 2026 г., 22:42 UTC

Отчет

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 февр. 2026 г., 22:24 UTC

Приобретения, слияния, поглощения

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 февр. 2026 г., 23:46 UTC

Обсуждения рынка

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 февр. 2026 г., 23:36 UTC

Обсуждения рынка

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 февр. 2026 г., 23:30 UTC

Обсуждения рынка

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 февр. 2026 г., 23:20 UTC

Обсуждения рынка

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 февр. 2026 г., 23:20 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

24 февр. 2026 г., 23:16 UTC

Отчет

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 февр. 2026 г., 23:13 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 февр. 2026 г., 23:12 UTC

Отчет

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 февр. 2026 г., 23:10 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 февр. 2026 г., 23:10 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 февр. 2026 г., 23:08 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 февр. 2026 г., 23:07 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 февр. 2026 г., 22:52 UTC

Отчет

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 февр. 2026 г., 22:46 UTC

Отчет

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 февр. 2026 г., 22:31 UTC

Приобретения, слияния, поглощения

Warner Receives New Bid From Paramount -- 3rd Update

24 февр. 2026 г., 22:29 UTC

Отчет

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 февр. 2026 г., 22:28 UTC

Отчет

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 февр. 2026 г., 22:27 UTC

Отчет

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 февр. 2026 г., 22:27 UTC

Отчет

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 февр. 2026 г., 22:25 UTC

Отчет

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 февр. 2026 г., 22:24 UTC

Отчет

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 февр. 2026 г., 22:23 UTC

Отчет

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 февр. 2026 г., 22:22 UTC

Отчет

Woolworths Interim Dividend 45 Australian Cents/Share

24 февр. 2026 г., 22:22 UTC

Отчет

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 февр. 2026 г., 22:21 UTC

Отчет

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение c конкурентами

Изменение цены

Vivani Medical Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

Покупка

Удержание

Продажа

Основано на мнении 0 аналитиков, присваивавших рейтинги акциям Vivani Medical – Данные за последние 3 месяца.

Финансовые показатели

О компании Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.